Eagle Asset Management Inc. Increases Holdings in Sanofi SA (SNY)

Eagle Asset Management Inc. raised its position in shares of Sanofi SA (NYSE:SNY) by 66.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,807 shares of the company’s stock after buying an additional 4,302 shares during the quarter. Eagle Asset Management Inc.’s holdings in Sanofi were worth $537,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Parallel Advisors LLC raised its position in shares of Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC raised its position in shares of Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the period. Bronfman E.L. Rothschild L.P. raised its position in shares of Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the period. Toronto Dominion Bank raised its position in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares during the period. Finally, Mraz Amerine & Associates Inc. acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $204,000. Hedge funds and other institutional investors own 9.09% of the company’s stock.

Sanofi SA (NYSE SNY) traded down $0.34 on Thursday, reaching $43.17. The company had a trading volume of 1,495,000 shares, compared to its average volume of 1,502,720. Sanofi SA has a 12-month low of $38.45 and a 12-month high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The firm has a market cap of $109,710.81, a PE ratio of 13.73, a P/E/G ratio of 2.40 and a beta of 0.86.

SNY has been the topic of a number of research reports. upgraded Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Morgan Stanley cut Sanofi from an “overweight” rating to an “underweight” rating in a research report on Friday, December 1st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Finally, Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and an average price target of $53.50.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/07/eagle-asset-management-inc-increases-holdings-in-sanofi-sa-sny.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

What are top analysts saying about Sanofi SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi SA and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit